BJG-05-039

Overview

BJG-05-039 is a PAK1 -selective degrader consisting of NVS-PAK1-1 ( HY-100519 ) conjugated to Lenalidomide ( HY-A0003 ). BJG-05-039 induces selective degradation of PAK1 . BJG-05-039 inhibits phosphorylation of MEK S298 , as well as inhibiting phosphorylation of ERK . BJG-05-039 has an anti-proliferative effect on PAK1-dependent cell lines.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > PAK | Products > Signaling Pathways > MEK | Products > Signaling Pathways > PERK

Product Information

• Catalog No.: HY-148821
• CAS No.: 3009849-06-0
• Molecular Formula: C41H44ClF3N8O5
• Molecular Weight: 821.29
• Purity: 98.06%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.04 mM); Suspended solution
• Availability: In-stock

Source

Original product source